Tag Archives: Phil Nadeau

Cowen & Co. Keeps a Buy Rating on Atara Biotherapeutics (ATRA)

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) today. The company’s shares closed last Monday at $14.67, close to its 52-week low of $10.38. According to TipRanks.com, Nadeau is a 5-star

PDL BioPharma (PDLI) Gets a Hold Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on PDL BioPharma (PDLI – Research Report), with a price target of $3.00. The company’s shares closed last Monday at $3.57. According to TipRanks.com, Nadeau

Cowen & Co. Sticks to Its Buy Rating for Immunomedics (IMMU)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Immunomedics (IMMU – Research Report), with a price target of $30.00. The company’s shares closed last Monday at $19.02. According to TipRanks.com, Nadeau is

Myovant Sciences (MYOV) Gets a Buy Rating from Cowen & Co.

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Myovant Sciences (MYOV – Research Report). The company’s shares closed last Monday at $10.99. According to TipRanks.com, Nadeau is a 4-star analyst with an

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Crispr Therapeutics AG (NASDAQ: CRSP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Crispr Therapeutics AG (CRSP – Research Report) with bullish sentiments. Vertex Pharmaceuticals (VRTX) In a

Cowen & Co. Initiates a Buy Rating on Cabaletta Bio (CABA)

Cabaletta Bio (CABA – Research Report) received a Buy rating from Cowen & Co. analyst Phil Nadeau today. The company’s shares closed last Monday at $13.79. According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.2%